In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer, with a price target of $28.00. According to TipRanks, Flynn is a 5-star analyst with an average return ...
A public health expert breaks down the details of the CDC delaying reporting of COVID-19 vaccine benefits, including study ...
The COVAX programme has signed deals for hundreds of millions of doses to vaccinate people in poor and lower-middle income ...
After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its ...
FairJourney Bio (FJBio), a global antibody discovery contract research organization (CRO), today announced the opening of its advanced cryo-electron microscopy (cryo-EM) structural biology facility in ...
Chief among its criticisms is Novavax's failure to build sales of its protein-based COVID-19 vaccine Nuvaxovid/Covovax, a ...
Shah Capital, which has agitated for change at the vaccine maker for years, is calling on fellow shareholders to end what it ...
"Your tenure has overseen a DESTRUCTION of shareholder value—a direct result of chronic operational shortcomings and failures ...
The messenger RNA (mRNA) market is undergoing significant expansion, driven by its versatile approach in treating and ...
Penn Medicine scientists blend AI and ingenuity to transform mRNA gene editing and personalized therapies redefining modern ...
Katalin Karikó, a Nobel Prize-winning scientist who pioneered mRNA research that led to life-saving vaccines during the COVID ...
Despite its numerous mutations, Cicada causes symptoms similar to those of previous variants: fever, cough, fatigue, runny ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results